IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Recurrent Rectal Carcinoma
SWOG Cancer Research Networkmonoclonal_antibodyPhase 2Active
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Recurrent Rectal Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sorafenib National Cancer Institute (NCI) | Phase 2 | B |
mk-2206 National Cancer Institute (NCI) | Phase 2 | CCC |
Nintedanib Roswell Park Cancer Institute | Phase 1/2 | CCC |
rg4733 National Cancer Institute (NCI) | Phase 2 | CCC |
Cediranib National Cancer Institute (NCI) | Phase 1 | CC |
Inno-206 Mayo Clinic | Early Phase 1 | C |
Sodium Thiosulfate Mayo Clinic | Early Phase 1 | C |
CIS-DIAMMINEDICHLOROPLATINUM II Mayo Clinic | Early Phase 1 | C |
Same molecule, other indications
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →